← All trials
NCT01836575
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2008
- Primary completion
- Jan 1, 2012
- Completion date
- Dec 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 228
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Government of BrazilLead sponsor
- National Cancer Institute, FranceOverall official - principal investigator
- Lifecenter HospitalOverall official - principal investigator
- Hospital Amaral CarvalhoOverall official - principal investigator
- Centro de Pesquisas Oncológicas - CEPONOverall official - principal investigator
- Eli LillyCollaborator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.